Stock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny

Stock Track

Feb 10

Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.

The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.

Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1177836469"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177836469\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177836469?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177836469","market":"sg","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.</p><p>The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.</p><p>Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-10 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.</p><p>The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.</p><p>Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1177836469","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177836469","pubTimestamp":1770737085,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health盘中暴跌5.10%，遭诺和诺德专利诉讼及监管审查","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}